The recently announced cash injection of £20 billion in real terms by 2023/24 comes at a welcome time for the NHS, which continues to struggle in the face of evolving health challenges. An ageing population and chronic conditions see patients spend increasingly longer in hospital and therefore the introduction of new medical innovations that can reduce bed-days and enable greater self-care among the patient population can have a profound effect. Despite this however, innovative medical technologies often struggle to be taken up across the NHS.

In this piece we explore the Accelerated Access Review, which seeks to ensure patients have access to innovative products faster, how it will be implemented and consider what’s next for the UK’s thriving MedTech sector.

NHS: The Accelerated Access Review

MORE
INSIGHT